PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW) oleh F Moreau, S Roy, M Khursheed, A Deshpande, C Vazquez-Mateo, EF Morand, VP Werth, A Bender, A Deshmukh, B Vaidyanathan, M Przetak, DR Pearson